Articles published by Egle Therapeutics

Egle Therapeutics Appoints John Celebi as Chief Executive Officer

January 07, 2026

From Egle Therapeutics

Via GlobeNewswire

Tickers SNSE

Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic Dermatitis

December 02, 2025

From Egle Therapeutics

Via Business Wire

Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs EGL-001 and EGL-002 With Poster Presentations at the 2025 AACR Annual Meeting

April 22, 2025

From Egle Therapeutics

Via Business Wire

Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030

March 17, 2025

From Egle Therapeutics

Via Business Wire

Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer

January 13, 2025

From Egle Therapeutics

Via Business Wire

Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting

October 25, 2024

From Egle Therapeutics

Via Business Wire

EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D., as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board Member Representative of Takeda Ventures

September 12, 2024

From EGLE Therapeutics

Via Business Wire

Egle Therapeutics Strengthens its Leadership Team with the Appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical Officer

March 27, 2024

From Egle Therapeutics

Via Business Wire

Egle Therapeutics Raises 40 Million € Series a to Develop First-In-Class T-regulatory Cells Therapies Based On Treg-starvers

October 22, 2021

From Egle Therapeutics

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.